Search

Your search keyword '"Futreal, Andrew"' showing total 890 results

Search Constraints

Start Over You searched for: Author "Futreal, Andrew" Remove constraint Author: "Futreal, Andrew"
890 results on '"Futreal, Andrew"'

Search Results

1. Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer

2. Author Correction: Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma

4. METI: deep profiling of tumor ecosystems by integrating cell morphology and spatial transcriptomics

6. Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

7. Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies

8. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma

9. The “Great Debate” at Immunotherapy Bridge 2021, December 1st–2nd, 2021

10. DCIS knowledge of women choosing between active surveillance and surgery for low-risk DCIS

11. Atlas of Metastatic Gastric Cancer Links Ferroptosis to Disease Progression and Immunotherapy Response

12. Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer

13. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance

14. Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy

15. PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma

16. Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring

17. Archival single-cell genomics reveals persistent subclones during DCIS progression

18. Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression

19. Proteogenomic landscape of gastric adenocarcinoma peritoneal metastases

20. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease

21. Clinical Characteristics and Cause of Death Among Hospitalized Decedents With Cancer and COVID-19

22. Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk

25. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial

27. Metagenomes of rectal swabs in larger, advanced stage cervical cancers have enhanced mucus degrading functionalities and distinct taxonomic structure

29. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

30. Mechanisms that clear mutations drive field cancerization in mammary tissue.

31. Patient–reported fatigue prior to treatment is prognostic of survival in patients with acute myeloid leukemia

32. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets

33. Supplemental Figure 1 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

34. Data from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

35. Supplementary Tables from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

36. TABLE 1 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

37. Supplemental Figure 2 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

38. Supplementary Table S6 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series

39. Data from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series

40. Supplementary Figure S4 from Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series

41. The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasion

42. Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features

43. Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series

44. Clonal dominance defines metastatic dissemination in pancreatic cancer

45. Future cancer research priorities in the USA: a Lancet Oncology Commission

46. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors

48. Mechanisms that clear mutations drive field cancerization in mammary tissue

49. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

50. Ductal carcinoma in situ develops within clonal fields of mutant cells in morphologically normal ducts.

Catalog

Books, media, physical & digital resources